Expanded Alternatives of CRISPR-Cas9 Applications in Immunotherapy of Colorectal Cancer

Overview

Journal Mol Diagn Ther

Specialties Molecular Biology
Pathology
Pharmacology

Date 2023 Nov 1

PMID 37907826

Authors

Ruben Arroyo-Olarte

Aranza Mejia-Munoz

Sonia Leon-Cabrera

Affiliations

Soon will be listed here.

Abstract

Immunotherapy for colorectal cancer (CRC) is limited to patients with advanced disease who have already undergone first-line chemotherapy and whose tumors exhibit microsatellite instability. Novel technical strategies are required to enhance therapeutic options and achieve a more robust immunological response. Therefore, exploring gene analysis and manipulation at the molecular level can further accelerate the development of advanced technologies to address these challenges. The emergence of advanced genome editing technology, particularly of clustered, regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein (Cas) 9, holds promise in expanding the boundaries of cancer immunotherapy. In this manuscript, we provide a comprehensive review of the applications and perspectives of CRISPR technology in improving the design, generation, and efficiency of current immunotherapies, focusing on solid tumors such as colorectal cancer, where these approaches have not been as successful as in hematological conditions.

References

Keller L, Werner S, Pantel K . Biology and clinical relevance of EpCAM. Cell Stress. 2019; 3(6):165-180. PMC: 6558934. DOI: 10.15698/cst2019.06.188. View

Caronni N, Piperno G, Simoncello F, Romano O, Vodret S, Yanagihashi Y . TIM4 expression by dendritic cells mediates uptake of tumor-associated antigens and anti-tumor responses. Nat Commun. 2021; 12(1):2237. PMC: 8046802. DOI: 10.1038/s41467-021-22535-z. View

Andrea A, Chiron A, Mallah S, Bessoles S, Sarrabayrouse G, Hacein-Bey-Abina S . Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment. Front Immunol. 2022; 13:830292. PMC: 8861853. DOI: 10.3389/fimmu.2022.830292. View

Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A . Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2009; 138(4):1429-40. DOI: 10.1053/j.gastro.2009.10.057. View

Aparicio C, Belver M, Enriquez L, Espeso F, Nunez L, Sanchez A . Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells. Int J Mol Sci. 2021; 22(21). PMC: 8583883. DOI: 10.3390/ijms222111781. View

Zhang C, Jia J, Heng G, Li Y, Wang M, Chen J . CD27 agonism coordinates with CD28 and 4-1BB signal to augment the efficacy of CAR-T cells in colorectal tumor. Med Oncol. 2023; 40(4):123. DOI: 10.1007/s12032-023-01959-1. View

Yau E, Kummetha I, Lichinchi G, Tang R, Zhang Y, Rana T . Genome-Wide CRISPR Screen for Essential Cell Growth Mediators in Mutant KRAS Colorectal Cancers. Cancer Res. 2017; 77(22):6330-6339. PMC: 5690866. DOI: 10.1158/0008-5472.CAN-17-2043. View

Shi L, Meng T, Zhao Z, Han J, Zhang W, Gao F . CRISPR knock out CTLA-4 enhances the anti-tumor activity of cytotoxic T lymphocytes. Gene. 2017; 636:36-41. DOI: 10.1016/j.gene.2017.09.010. View

Zhao Z, Shi L, Zhang W, Han J, Zhang S, Fu Z . CRISPR knock out of programmed cell death protein 1 enhances anti-tumor activity of cytotoxic T lymphocytes. Oncotarget. 2018; 9(4):5208-5215. PMC: 5797044. DOI: 10.18632/oncotarget.23730. View

10.

Webber B, Lonetree C, Kluesner M, Johnson M, Pomeroy E, Diers M . Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nat Commun. 2019; 10(1):5222. PMC: 6864045. DOI: 10.1038/s41467-019-13007-6. View

11.

Wei X, Lai Y, Li J, Qin L, Xu Y, Zhao R . PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. Oncoimmunology. 2017; 6(3):e1284722. PMC: 5384358. DOI: 10.1080/2162402X.2017.1284722. View

12.

Yan Z, Zhang H, Cao J, Zhang C, Liu H, Huang H . Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment. Front Immunol. 2021; 12:611366. PMC: 7940756. DOI: 10.3389/fimmu.2021.611366. View

13.

Roper J, Tammela T, Malli Cetinbas N, Akkad A, Roghanian A, Rickelt S . In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nat Biotechnol. 2017; 35(6):569-576. PMC: 5462879. DOI: 10.1038/nbt.3836. View

14.

Wilk C, Effenberg L, Abberger H, Steenpass L, Hansen W, Zeschnigk M . CRISPR/Cas9-mediated demethylation of FOXP3-TSDR toward Treg-characteristic programming of Jurkat T cells. Cell Immunol. 2021; 371:104471. DOI: 10.1016/j.cellimm.2021.104471. View

15.

Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D . Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2008; 27(2):186-92. DOI: 10.1200/JCO.2008.18.7229. View

16.

Henke E, Nandigama R, Ergun S . Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy. Front Mol Biosci. 2020; 6:160. PMC: 7025524. DOI: 10.3389/fmolb.2019.00160. View

17.

Sterner R, Sterner R . CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021; 11(4):69. PMC: 8024391. DOI: 10.1038/s41408-021-00459-7. View

18.

Massard C, Gordon M, Sharma S, Rafii S, Wainberg Z, Luke J . Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016; 34(26):3119-25. PMC: 5569690. DOI: 10.1200/JCO.2016.67.9761. View

19.

Guo G, Wang Y, Zhou Y, Quan Q, Zhang Y, Wang H . Immune cell concentrations among the primary tumor microenvironment in colorectal cancer patients predicted by clinicopathologic characteristics and blood indexes. J Immunother Cancer. 2019; 7(1):179. PMC: 6625045. DOI: 10.1186/s40425-019-0656-3. View

20.

Jang G, Kweon J, Kim Y . CRISPR prime editing for unconstrained correction of oncogenic KRAS variants. Commun Biol. 2023; 6(1):681. PMC: 10313713. DOI: 10.1038/s42003-023-05052-1. View